Biological

BIOLOGICAL13 trials

Sponsors

Stony Brook University, DiaVacs, Inc., Assistance Publique - Hôpitaux de Paris, University Hospital, Lille, Central Hospital, Nancy, France

Conditions

Autonomic Nervous System DiseasesBone DisorderBronchopulmonary DysplasiaCell TherapyCelluliteCovid19 and PregnancyCrohn's DiseaseExtra-Corporeal-Life-Support ( ECLS)

Phase 1

Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy

DiaVacs, Inc.Treatment of Type I Diabetes Mellitus.

Start: 2013-10-31Target: 90Updated: 2013-10-23

Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A

Not yet recruitingNCT04418414

Expression Therapeutics, LLCHemophilia A

Start: 2024-09-01End: 2039-08-31Target: 7Updated: 2024-02-20

Clinical Trial of GAIA-102 for Advanced and Relapse NSCLC

TerminatedNCT05207371

GAIA BioMedicine Inc.Cell Therapy, NSCLC

Start: 2021-12-01End: 2026-03-06Updated: 2026-09-03

Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors

RecruitingNCT05608148

Kyushu UniversityPediatric Solid Tumors, Refractory/Relapse Neuroblastoma

Start: 2022-10-26End: 2027-08-25Target: 61Updated: 2026-08-07

Phase 2

Collagenase in the Treatment of Cellulite

Stony Brook UniversityCellulite

Start: 2013-02-28End: 2014-03-31Target: 20Updated: 2012-12-12

Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease

CompletedNCT04542967

Hospital Central MilitarSevere COVID-19 Disease

Start: 2020-06-23End: 2020-09-30Updated: 2021-05-10

Unknown Phase

Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary

RecruitingNCT02828202

Assistance Publique - Hôpitaux de ParisMalignant Melanoma

Start: 2013-02-28End: 2026-03-31Target: 6000Updated: 2025-02-11

COmparison of MicroBiota AccordIng to Age in Crohn's Disease (COMeBACk)

CompletedNCT02839317

University Hospital, LilleCrohn's Disease

Start: 2016-05-09End: 2022-12-22Updated: 2025-12-16

Impact of Adrenoreceptor Expressions on Inflammatory Pattern in Refractory Cardiogenic Shock Under VA ECMO

CompletedNCT03327493

Central Hospital, Nancy, FranceAutonomic Nervous System Diseases, Extra-Corporeal-Life-Support ( ECLS), Inflammation +1

Start: 2017-10-10End: 2022-05-24Updated: 2023-04-19

Relationship Between Fungal Colonization and Severe Bronchopulmonary Dysplasia

CompletedNCT05152875

Centre Hospitalier Sud FrancilienBronchopulmonary Dysplasia, Extreme Prematurity, Fungal Infection

Start: 2022-03-21End: 2022-05-31Updated: 2024-11-26

Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Aibin Liang，MD，Ph.D.Plasma Cell Leukemia in Relapse, Relapsed and/or Refractory Multiple Myeloma

Start: 2023-04-12End: 2026-01-01Target: 12Updated: 2023-06-08

Stress in Pregnancy During the Covid19 Pandemic and Impact on the Newborn Neurodevelopment

Active, not recruitingNCT06362486

Fundación Pública Andaluza para la gestión de la Investigación en SevillaCovid19 and Pregnancy

Start: 2021-08-01End: 2024-08-01Target: 1000Updated: 2024-04-12

Clinico-biological Collection of Bone, Calcium and Growth Plate Pathologies

RecruitingNCT06444503

University Hospital, ToulouseBone Disorder

Start: 2024-09-16End: 2034-09-16Target: 350Updated: 2026-06-05

Related Papers

Continuous Intrathecal Infusion of Nivolumab in Advanced Melanoma With Concomitant Leptomeningeal Disease: Efficacy, Safety, and Pharmacokinetics

Neurosurgery2026-02-04

BioMEL: a translational research biobank of melanocytic lesions and melanoma

BMJ Open2024-02-016 citations

782-F Pseudoprogression and subsequent shrinkage of refractory/relapsed pediatric solid tumors induced by GAIA-102: an interim report of the single-agent cohort in Phase I clinical trial

2023-10-31

Efficacy and tolerance of systemic therapies in metastatic melanoma of unknown primary versus known cutaneous: A multicenter retrospective study from the MelBase French Cohort.

Journal of Clinical Oncology2022-06-01

ZEB1 transcription factor promotes immune escape in melanoma

Journal for ImmunoTherapy of Cancer2022-03-0195 citations

Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data<sup>☆</sup>.

2020-12-3022 citations

Does body mass index really predict the response to systemic therapies in metastatic melanoma: A multicenter study from the MelBase French National Cohort?

Journal of Clinical Oncology2020-05-201 citations

Progression and hyperprogression after anti-PD1 therapy for unresectable stage III or IV melanoma patients.

Journal of Clinical Oncology2019-05-20